NDV-HXP-S鼻内接种在已接种成人中的1期试验
该1期试验在纽约单中心纳入35名无新冠感染史且已接种疫苗的健康成人,经鼻内、肌内或同时两种途径接种低或高剂量NDV-HXP-S或安慰剂。疫苗安全耐受,仅见1-2级不良事件;安慰剂组抗体滴度下降,而疫苗组维持或提升血清IgG和中和活性,唾液sIgA小幅上升。研究未按统计学显著性设计。
要点
- NDV-HXP-S经鼻内、肌内或联合接种安全耐受,仅见1-2级不良事件。
- 疫苗组维持或提升血清IgG和中和活性,安慰剂组抗体滴度下降。
- 唾液sIgA小幅上升,基线CD4+ T细胞活性低者第28天增加。
核心结论
- 活NDV-HXP-S在该小样本1期研究中安全耐受。
- 探索性免疫原性分析显示系统与黏膜免疫应答存在差异,支持在更大对照研究中评估更新配方。
研究设计与样本
- 1期试验,在纽约单中心纳入35名无新冠感染史且既往接种疫苗的健康成人(2022年2月至2024年4月)。
- 参与者经鼻内、肌内或同时两种途径接种低或高剂量NDV-HXP-S或安慰剂,安全性监测365天,血清和唾液免疫应答测至第84天。
主要发现
- 全部35名参与者完成随访,仅见1-2级不良事件。
- 安慰剂接受者抗体滴度下降,而NDV-HXP-S维持或提升血清IgG和中和活性。
- 唾液sIgA小幅上升;基线CD4+ T细胞活性低的参与者在第28天出现增加。
- 研究未按统计学显著性设计。
临床怎么用
- 提示活NDV-HXP-S鼻内接种方案安全耐受,并可能维持或提升已接种成人的血清抗体应答。
- 黏膜免疫应答有限,需在更大对照研究中进一步评估更新配方。
局限性
- 小样本1期研究,未按统计学显著性设计。
- 免疫原性分析为探索性,系统与黏膜应答存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Newcastle disease virus hexapro spike (NDV-HXP-S) is a recombinant vaccine designed to elicit both systemic and mucosal immunity against SARS-CoV-2. Intramuscular vaccines protect against severe disease but provide limited mucosal protection. We conducted a Phase 1 trial of live NDV-HXP-S administered intranasally (IN), intramuscularly (IM), or simultaneously (IN+IM) in previously vaccinated adults. METHODS: Thirty-five healthy adults without prior COVID-19 were enrolled at a single site in New York City (Feb 2022-Apr 2024). Participants received low- or high-dose NDV-HXP-S via IN, IM, or IN+IM routes, or placebo. Safety was monitored for 365 days; immune responses in serum and saliva were measured through day 84. FINDINGS: All 35 participants completed follow-up. NDV-HXP-S was safe and well tolerated, with only grade 1-2 adverse events. Placebo recipients showed waning antibody titers, whereas NDV-HXP-S maintained or boosted serum IgG and neutralizing activity. Salivary sIgA rose modestly. Participants with low baseline CD4+ T-cell activity exhibited increases by day 28. The study was not powered for statistical significance. INTERPRETATION: Live NDV-HXP-S was safe and well tolerated in this small Phase 1 study. Exploratory immunogenicity analyses showed variable systemic and mucosal responses, supporting further evaluation of updated NDV-HXP-S formulations in larger controlled studies. FUNDING: Supported by the Icahn School of Medicine Dean's Philanthropic Fund, CastleVax Inc., Mount Sinai CTSA (UL1TR004419), and philanthropic and federal grants. TRIAL REGISTRATION: ClinicalTrials.govNCT05181709.
引用
- Liu STH, González-Domínguez I, Martínez-Pérez A, et al. Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults. Vaccine. 2026. PMID: 42378814. doi:10.1016/j.vaccine.2026.128870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。